JenaValve Launches Trilogy Heart Valve in US for Aortic Regurgitation

JenaValve has officially launched its Trilogy heart valve system in the United States, marking a significant advancement in the treatment of aortic regurgitation (AR). With the successful completion of the first commercial procedures, JenaValve’s innovative technology now offers hope to patients deemed at high risk for surgical aortic valve replacement. This breakthrough could transform treatment options and improve outcomes for a largely underserved patient population. 

Trilogy is the first and only transcatheter heart valve system in the U.S. specifically approved for patients with symptomatic, severe aortic regurgitation. This sets it apart from existing solutions by companies like Edwards and Medtronic, which primarily address aortic stenosis. Unlike traditional transcatheter aortic valve replacement systems that rely on calcification for anchoring, Trilogy employs unique locator technology to securely attach to native leaflets, addressing AR’s anatomical challenges. JenaValve’s leadership foresees a transformative impact on how aortic regurgitation is identified, diagnosed, and treated in the U.S. The Trilogy system’s innovative design and technology promise to improve patient outcomes and safety, addressing a critical unmet need in cardiac care.

As JenaValve introduces the Trilogy system across the U.S., it sets a new standard for treating severe aortic regurgitation. This milestone represents a major leap forward in cardiac care, offering new hope for patients and underscoring the company’s commitment to innovation and individualized treatment approaches.